OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Drilon on the FDA Approval of Selpercatinib in RET Fusion+ Solid Tumors

November 17th 2022

Alexander Drilon, MD, discusses the significance of the FDA approval of selpercatinib in RET fusion–positive solid tumors.

Dr. Ramakrishnan on the Evolving Landscape of CAR T-cell Therapy in DLBCL

November 17th 2022

Praveen Ramakrishnan, MD, MS, discusses the evolving landscape of CAR T-cell therapy in diffuse large B-cell lymphoma.

Dr. Conlin on the Benefits of Trastuzumab Deruxtecan in HER2-Low Breast Cancer

November 17th 2022

Alison K. Conlin, MD, discusses the benefits of trastuzumab deruxtecan in HER2-low breast cancer.

Dr. Lin on Second-line CAR T-cell Therapy in Relapsed/Refractory DLBCL

November 16th 2022

Richard J. Lin, MD, PhD, discusses the manufacturing considerations that factor into the CAR T-cell decision-making process in diffuse large B-cell lymphoma, the importance of open communication between community and referral physicians, and how early referral leads to optimal patient outcomes with CAR T-cell therapy.

Dr. Westin on Second-line CAR T-cell Therapy in Relapsed/Refractory DLBCL

November 16th 2022

Jason Westin, MD, FACP, discusses reasons to refer patients with diffuse large B-cell lymphoma to second-line CAR T-cell therapy, CAR T-cell eligibility criteria, and high-risk disease features that may further support the use of CAR T-cell therapy in the second line, rather than chemotherapy.

Dr. McKay on Future Directions For mRCC Research

November 16th 2022

Rana R. McKay, MD, discusses the potential impact of triplet therapies in the treatment paradigm for metastatic renal cell carcinoma and identifies several other areas for further study.

Dr. Schiller on Addressing Unmet Needs in Myelofibrosis Treatment

November 16th 2022

Gary J. Schiller, MD, discusses several areas of unmet need in myelofibrosis, and how to potentially address these challenges.

Dr. Binder on the Use of Immune Checkpoint Inhibitors in Endometrial Cancer Treatment

November 16th 2022

Pratibha Binder, MD, discusses how the introduction of novel immune checkpoint inhibitors into frontline treatment strategies could ameliorate unmet needs in endometrial cancer.

Dr. Salani on Updates in Treating Endometrial Cancer

November 15th 2022

Ritu Salani, MD, MBA, discusses updates in treating endometrial cancer.

Dr. Goy on the Clinical Implications of Treating Indolent MCL

November 15th 2022

Andre H. Goy, MD, discusses the clinical implications of treating indolent mantle cell lymphoma.

Dr. Schmid on the Rationale for the RACE IT Trial in Advanced Urothelial Carcinoma

November 15th 2022

Sebastian C. Schmid, MD, discusses the rationale for the phase 2 RACE IT trial in urothelial carcinoma.

Dr. Matulonis on the FDA Approval of Mirvetuximab Soravtansine in Frα+ Platinum-resistant Ovarian Cancer

November 15th 2022

Ursula A. Matulonis, MD, discusses the significance of the FDA approval of mirvetuximab soravtansine-gynx in patients with folate receptor α–positive, platinum-resistant ovarian cancer.

Dr. Gupta on the Investigation of Enfortumab Vedotin With or Without Additional Therapy in mUC

November 14th 2022

Shilpa Gupta, MD, discusses the investigation of enfortumab vedotin with or without additional therapy in cisplatin-ineligible metastatic urothelial carcinoma.

Dr. Saenz on the Need for Ongoing Research Efforts in Cervical Cancer

November 14th 2022

Cheryl Saenz, MD, discusses the need for ongoing research efforts in cervical cancer.

Dr. Epstein-Peterson on Pivotal Clinical Trials in MCL

November 14th 2022

Zachary Epstein-Peterson, MD, discusses pivotal clinical trials in the treatment of patients with mantle cell lymphoma.

Dr. Halmos on Trastuzumab Deruxtecan in NSCLC

November 14th 2022

Balazs Halmos, MD, discusses the importance of testing for HER2 mutations and exon 20 insertions, which are emerging new targets in non–small cell lung cancer, and how fam-trastuzumab deruxtecan-nxki meets needs for patients with HER2-mutant disease.

Dr. Kris on Immunotherapy in NSCLC Without Driver Mutations

November 14th 2022

Mark G. Kris, MD, discusses the role of immunotherapy in patients with non–small cell lung cancer without driver mutations.

Dr. Antonarakis on the Benefits of Genetic Testing for Select Patients With Prostate Cancer

November 14th 2022

Emmanuel Antonarakis, MD, discusses the benefits of somatic and germline testing for patients with prostate cancer.

Dr. Siefker-Radtke on Unmet Needs in Frontline Urothelial Cancer Treatment

November 14th 2022

Arlene O. Siefker-Radtke, MD, discusses key therapeutic developments aimed at addressing unmet needs in metastatic urothelial carcinoma treatment.

Dr. Schulte on the Prevalence of TSC1/TSC2 Mutations in Cancer

November 14th 2022

Brian Schulte, MD, discusses the prevalence of TSC1/TSC2 mutations in cancer.